Xing D, Das R Gaines, Newland P, Corbel M
Division of Bacteriology, National Institute for Biological Standards and Control, Blanche Lane South Mimms, Hertfordshire, EN6 3QG, Potters Bar, UK.
Vaccine. 2002 Oct 4;20(29-30):3535-42. doi: 10.1016/s0264-410x(02)00338-9.
Pertussis toxin (PT) in its detoxified form is an important antigenic component of both acellular and whole cell pertussis vaccines. Limits on the content of active PT in acellular vaccines are set in official monographs (EP, WHO, USP) and evidence of compliance is therefore, required by regulatory authorities. The two assay methods which are currently used by most manufacturers and official national control laboratories to monitor residual PT activity in acellular pertussis vaccines (and also in whole cell vaccines) are histamine sensitising (HIST) assays and Chinese hamster ovary (CHO) cell assays. Currently, different reference preparations of PT are used by individual laboratories for these tests. We therefore organised an international collaborative study to examine, by these two assay methods, two freeze-dried purified preparations of PT, one preparation in ampoules coded JNIH-5 and one preparation in ampoules coded 90/518, together with in-house reference (IHR) preparations in current use. Data from this study confirm that both JNIH-5 and 90/518 show biological activity both in HIST assays and in CHO-cell assays. Both HSD50 and ED50 values obtained in this study differ significantly between laboratories and thus show that biological activity is not determined by the nominal masses of preparations. Estimates of relative potency of 90/518 in terms of JNIH-5 per ampoule for the HIST assays do not differ significantly between laboratories. The overall mean estimates of relative potency of 90/518 in terms of JNIH-5 do not differ significantly between the two methods. Data from this study further indicate that the biological activity of different preparations was not directly related to their stated protein content. The use of protein content to indicate the level of PT activity in different preparations would give misleading results. Thus, use of a common standard is shown to greatly improve between laboratory agreement of estimates.
脱毒形式的百日咳毒素(PT)是无细胞百日咳疫苗和全细胞百日咳疫苗的重要抗原成分。官方专著(欧洲药典、世界卫生组织、美国药典)对无细胞疫苗中活性PT的含量设定了限制,因此监管当局要求提供合规证据。目前,大多数制造商和国家官方控制实验室用于监测无细胞百日咳疫苗(以及全细胞疫苗)中残留PT活性的两种检测方法是组胺致敏(HIST)检测和中国仓鼠卵巢(CHO)细胞检测。目前,各个实验室在这些检测中使用不同的PT参考制剂。因此,我们组织了一项国际协作研究,通过这两种检测方法,对两种冻干纯化的PT制剂进行检测,一种制剂装在编码为JNIH-5的安瓿中,另一种制剂装在编码为90/518的安瓿中,同时检测当前使用的内部参考(IHR)制剂。这项研究的数据证实,JNIH-5和90/518在HIST检测和CHO细胞检测中均显示出生物活性。在本研究中,不同实验室获得的HSD50和ED50值差异显著,因此表明生物活性不是由制剂的标称质量决定的。在HIST检测中,各实验室对每安瓿90/518相对于JNIH-5的相对效价估计差异不显著。两种方法对90/518相对于JNIH-5的相对效价总体平均估计差异不显著。这项研究的数据进一步表明,不同制剂的生物活性与其规定的蛋白质含量没有直接关系。用蛋白质含量来表示不同制剂中PT活性水平会得出误导性结果。因此,使用通用标准可显著提高实验室之间估计值的一致性。